Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 9
Submit an article Journal homepage
1,051
Views
13
CrossRef citations to date
0
Altmetric
Oncology

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

Jorge E. CortesDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USA;
,
Bogdan MuresanIngress-Health, Rotterdam, The Netherlands; Correspondence[email protected]
,
Carla MamoloPatient & Health Impact, Pfizer Inc., Groton, CT, USA; ORCID Iconhttp://orcid.org/0000-0001-5321-561X
ORCID Icon,
Joseph C. CappelleriGlobal Biometrics & Data Management, Pfizer Inc., Groton, CT, USA;
,
Rocco J. CrescenzoWorldwide Research & Development, Pfizer Inc., Walton Oaks, UK (at the time of this research);
,
Yun SuPatient & Health Impact, Pfizer Inc, New York, NY, USA (at the time of this research);
,
Carlo Gambacorti-PasseriniDepartment of Hematology, University of Milano Bicocca, Monza, Italy;
,
Bart HeegIngress-Health, Rotterdam, The Netherlands;
&
B. Douglas SmithDepartment of Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA
 show all
Pages 1615-1622 | Received 23 Oct 2018, Accepted 05 Apr 2019, Published online: 15 May 2019

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Bogdan Muresan, Carla Mamolo, Joseph C. Cappelleri, Eric Leip, Andrea Viqueira & Bart Heeg. (2021) An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion 37:5, pages 801-809.
Read now
Fiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, Irene Colasanto, Matilde Scaldaferri, Francesco Cattel, Francesca Federici, Chiara Rossi, Katiuscia Di Biagio, Anna Rita Scortechini, Felice Musicco, Giancarlo Torquati, Angela Frazzetto, Antonietta Vozza, Caterina de Rosa, Rosaria Lanzillo, Maria Monteverde, Luigia Luciano, Fabrizio Pane, Arianna Pasquazi, Maria Grazia Celeste, Maria Cantonetti, Luca Franceschini, Manuela Rizzo & Alberto Costantini. (2021) Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion 37:3, pages 477-481.
Read now
Jashin J. Wu, Jes B. Hansen, Dharm S. Patel, Nanna Nyholm, Karen A. Veverka & Andrine R. Swensen. (2020) Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. Journal of Medical Economics 23:6, pages 641-649.
Read now

Articles from other publishers (10)

Mohan Bajranglal Agarwal, Manthanathu Joseph John, Punit Jain, Ashok Kumar Vaid, Ajay Bapna, Maheboob Basade, Palanki Satya Dattatreya, Anupam Chakrapani, Vijay Ramanan, R. Varadarajan, Murali Subramanian, Chirag Aniruddha Shah, Narayanakutty Warrier, Subhaprakash Sanyal, Tyavanagi Shankarmurthy Ashwin & Nagendra Ramanjinappa. (2022) The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective. Indian Journal of Medical and Paediatric Oncology.
Crossref
Richie R. Bhandare, Bulti Bakchi, Dilep Kumar Sigalapalli & Afzal B. Shaik. (2022) An overview of in silico methods used in the design of VEGFR-2 inhibitors as anticancer agents . Physical Sciences Reviews 0:0.
Crossref
Lydia Ntari, Christoforos Nikolaou, Ksanthi Kranidioti, Dimitra Papadopoulou, Eleni Christodoulou-Vafeiadou, Panagiotis Chouvardas, Florian Meier, Christina Geka, Maria C. Denis, Niki Karagianni & George Kollias. (2021) Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment. Journal of Translational Medicine 19:1.
Crossref
Jorge Cortes, Carolina Pavlovsky & Susanne Saußele. (2021) Chronic myeloid leukaemia. The Lancet 398:10314, pages 1914-1926.
Crossref
B. Muresan, C. Mamolo, J. C. Cappelleri, M. J. Postma & B. Heeg. (2021) Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Applied Health Economics and Health Policy.
Crossref
Philip Cohen, Darren Cross & Pasi A. Jänne. (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery 20:7, pages 551-569.
Crossref
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew Frederickson & Bilal Piperdi. (2021) Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison. Lung Cancer 155, pages 175-182.
Crossref
Alexandra Lovell, Elias Jabbour, Jorge Cortes & Hagop Kantarjian. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia 61 76 .
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson & Bilal Piperdi. (2020) A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC. Cancers 12:12, pages 3648.
Crossref
Carlo Gambacorti-Passerini, Philipp le Coutre & Rocco Piazza. (2020) The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncology 16:2, pages 4395-4408.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.